- Pressemitteilung BoxID 122968
Profos introduces EndoGrade™ Ovalbumin
Today Profos AG announced the launch of EndoGrade™ Ovalbumin with highest quality (endotoxin conc. < 1 EU/mg) for in vivo and in vitro immunological studies
With the first of the globally unique EndoGrade™ products – with lowest endotoxin content – Profos sets new quality guidelines for reagents in immunology and cell culture.
The glycoprotein ovalbumin is the main constituent in egg white. Currently ovalbumin is one of the extensively used proteins in animal studies and also an established model allergen for airway hyper-responsiveness (AHR). Using its proprietary technology EndoTrap® Profos AG established an efficient endotoxin removal process to provide ovalbumin with lowest endotoxin content. The product is designed to give researchers the ability to ensure accurate results by avoiding side effects by endotoxin stimulation.
With EndoGrade™ Ovalbumin Profos takes another step to become a global market leader in the field of endotoxin removal systems and high-quality endotoxin-free products. Further products are in development and will expand the growing portfolio continuously.
Über Profos AG
Profos AG, founded in 2000, employs a total of 58 permanents staff and is certified according to ISO 9001:2000 and ISO13485:2003. Profos’ core competency is to exploit the principles of bacteriophage biology for pharmaceutical, diagnostic and research applications.